Approximately US$2.4 Billion is Currently Spent on Hypnotics and Sedatives in the Treatment of Insomnia - CNS Drug Discoveries: What the Future Holds Sleep Disorders.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47411) has announced the addition of CNS See Continuous net settlement. CNS See continuous net settlement (CNS). Drug Discoveries: What The Future Holds Sleep Disorders Sleep Disorders Definition Sleep disorders are a group of syndromes characterized by disturbance in the patient's amount of sleep, quality or timing of sleep, or in behaviors or physiological conditions associated with sleep. Chapter from Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. to their offering. This chapter of CNS Drug Discoveries focuses on the developments in the insomnia market and the substantial changes beginning to take place. The insomnia market is a maturing market and the author believes the landscape will change dramatically over the next five years as the market enters a transition phase and becomes more fragmented. The author forecasts it will grow to nearly US$6 billion by 2012 driven by a number of factors including the launch of new formulations, new drug classes, patient dynamics (ageing patient population) and changes in the way insomnia is treated. Sleep disorders cover a range of problems, the best known types being insomnia, sleep apnoea and restless legs syndrome Restless Legs Syndrome Definition Restless legs syndrome (RLS) is characterized by unpleasant sensations in the limbs, usually the legs, that occur at rest or before sleep and are relieved by activity such as walking. . Insomnia is the most prevalent sleep disorder Sleep disorder Any condition that interferes with sleep. At least 84 have been identified, according to the American Sleep Disorders Association. Mentioned in: Insomnia, Night Terrors and it is estimated to affect over 37 million US citizens and over 100 million people worldwide with approximately 25% of elderly people and 15% of the general population suffering from the condition. Studies suggest that less than 20% of insomniacs seek help and less than 20% of sufferers are prescribed a medication from their doctor. Global insomnia market Approximately US$2.4 billion is currently spent on hypnotics and sedatives in the treatment of insomnia, the 10th largest segment of CNS drug sales. The global market for insomnia drugs is unevenly distributed. In 2005, the US insomnia market accounted for 66% of the global market compared to 24% in Europe and 10% in the rest of world (largely Japan). This is mainly due to the pricing differential between the European and the US market. GABA-A receptor agonists (non-benzodiazepines) continue to remain the cornerstone for the treatment of both acute and chronic insomnia. However, the launch of several new products over the next 3 years will help to increase patient awareness, particularly in the elderly. Content Outline: INSOMNIA EXECUTIVE SUMMARY THE FACTS PATIENT STATISTICS PATIENT MODEL DRUG GROWTH DRIVERS DRUG GROWTH RISKS/DAMPNERS GLOBAL INSOMNIA MARKET GLOBAL SALES SPLIT CURRENT TREATMENTS ANALYSIS OF LEADING BRANDS GABA-A Receptor Agonists Melatonin Receptor A melatonin receptor is a G protein-coupled receptor (GPCR) which binds melatonin.[1] Three types of melatonin receptor have been cloned. The MT1 (or Mel1a or MTNR1A) and MT2 (or Mel1b Agonist agonist /ag·o·nist/ (ag´ah-nist) 1. one involved in a struggle or competition. 2. agonistic muscle. 3. GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012 NEW DRUGS IN R&D ANALYSIS OF PHASE III DRUGS GLOBAL SALES FORECASTS OF PHASE III INSOMNIA DRUGS 2006 - 2012 ANALYSIS OF PHASE II DRUGS 2A 5-HT2A RECEPTOR ANTAGONISTS GABA-A MODULATORS MELATONIN melatonin: see pineal gland. melatonin Hormone secreted by the pineal gland of most vertebrates. It appears to be important in regulating sleeping cycles; more is produced at night, and test subjects injected with it become sleepy. ANALOGUE GLOBAL SALES FORECASTS OF PHASE II INSOMNIA DRUGS 2006 - 2012 COMPETITOR RATIO ANALYSIS - COMPANIES DISCONTINUATION dis·con·tin·u·a·tion n. A cessation; a discontinuance. Noun 1. discontinuation - the act of discontinuing or breaking off; an interruption (temporary or permanent) discontinuance OF DRUGS INSOMNIA APPENDIX 1 INSOMNIA APPENDIX 2 INSOMNIA APPENDIX 3 INSOMNIA APPENDIX 4 INSOMNIA APPENDIX 5 INSOMNIA GLOSSARY INSOMNIA REFERENCES Acronyms For more information visit http://www.researchandmarkets.com/reports/c47411 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion